AI-generated analysis. Always verify with the original filing.
Enzon Pharmaceuticals, Inc. filed an 8-K on March 11, 2026, disclosing entry into the Ninth Amendment to the Section 382 Rights Agreement on March 10, 2026, a material definitive agreement under Item 1.01. The filing also covers Item 3.03 and Item 7.01 regarding a press release on March 11, 2026, announcing an extension to the expiration date for the exchange offer, with Exhibit 4.1 attached.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On March 10, 2026, Enzon Pharmaceuticals, Inc. (the “ Company ”) entered into the Ninth Amendment to the Section 382
. Item 7.01 Regulation FD Disclosure. On March 11, 2026, the Company issued a press release announcing an extension to the expiration date for the exchange offe
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 4.1 Ninth Amendment to the Section 382 Rights Agreement, dated as of March 10, 2026, by and
Material Agreement